Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus

What Was Tested

This randomized controlled trial paper looks at Angiotensin II in the context of low blood pressure and orthostatic hypotension.

To compare the effects of chronic glibenclamide therapy and placebo on blood pressure and cardiovascular responsiveness in patients with non-insulin-dependent diabetes.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Fourteen patients with non-insulin-dependent diabetes mellitus, seven of whom were receiving angiotensin converting enzyme inhibitor therapy, received glibenclamide or placebo for 1 month in a double-blind, randomized crossover study.

At the end of each treatment period patients attended for studies of forearm vascular responsiveness to intra-brachial arterial infusions of angiotensin II, acetylcholine, sodium nitroprusside and noradrenaline, responses of blood pressure to intravenous infusions of noradrenaline and angiotensin II and 24 h ambulatory blood pressure monitoring.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

The timeline in the abstract includes 1 month.

What Was Measured

Topics PubMed links to this paper include Acetylcholine, Angiotensin II, Blood Pressure, Diabetes Mellitus, Type 2, Forearm, Glyburide and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in people with low blood pressure and orthostatic hypotension over 1 month.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1998 (Journal of hypertension), a journal based in Netherlands.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.